免疫肿瘤学转化网络（IOTN）于2018年作为癌症登月行动（Cancer MoonshotSM）的一部分建立，2022年，拜登总统设立了新目标，即在25年内将癌症死亡率降低一半，并改善癌症患者和癌症幸存者的生活。IOTN致力于加快癌症免疫学研究从实验室到床边的转化，并改善成人人群中各类癌症的免疫治疗效果。IOTN独特的结构和团队科学方法旨在加快发现和评估新的基于免疫的治疗和预防策略。本文介绍了IOTN迄今取得的进展，包括新的倡议和开发一系列资源以推动癌症免疫学研究。我们总结了IOTN研究者的新见解，其中一些见解适用于多种癌症类型的转化。展望未来，我们确定了免疫肿瘤学概念转化为临床试验的障碍，以及适合高产出投资的行动和改进的关键领域。根据这些经验，我们建议采用新的国立卫生研究院（NIH）资金机制和开发新的资源来应对这些障碍。© The Author(s) 2023. Published by Oxford University Press.

The Immuno-Oncology Translational Network (IOTN) was established in 2018 as part of the Cancer MoonshotSM, and in 2022 President Biden set new goals to reduce the cancer death rate by half within 25 years and improve lives of people with cancer and cancer survivors. The IOTN is focused on accelerating translation of cancer immunology research from bench to bedside and improving immunotherapy outcomes across a wide array of cancers in the adult population. The unique structure and team science approach of the IOTN is designed to accelerate discovery and evaluation of novel immune-based therapeutic and prevention strategies. In this article, we describe IOTN progress to date, including new initiatives and the development of a robust set of resources to advance cancer immunology research. We summarize new insights by IOTN researchers, some of which are ripe for translation for several types of cancers. Looking to the future, we identify barriers to the translation of immuno-oncology concepts into clinical trials and key areas for action and improvements that are suitable for high-yield investments. Based on these experiences, we recommend novel NIH funding mechanisms and development of new resources to address these barriers.© The Author(s) 2023. Published by Oxford University Press.